The COSMOS study published in Cancer Research Communications highlights Guardant Reveal's potential.
Guardant Health Inc has announced the publication of its COSMOS study in Cancer Research Communications, validating the utility of its Guardant Reveal™ liquid biopsy test for predicting recurrence in melanoma. This development could influence treatment decisions and patient monitoring in oncology, positioning Guardant Health favorably in the market.
Advertisement
Guardant Health Inc
GH.US
GH.US
Guardant Health Inc
WealthAwesomeMarket cap
$25.12B
52W high
$187.69
52W low
$61.00
1W change
+5.58%
Beta
1.58
Analyst Price Targets
Based on analyst covering GH · as of Oct 6, 2026
Wall Street analysts forecast GH stock price to rise 1358.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$199.04
+1358.2% Upside
Previously C$197.44 on Oct 5, 2026
Current Price
C$13.65
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GH's historical volatility
30-Day Vol
42.7%
Annualized
90-Day Vol
49.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$223.82
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$198.70 | C$171.46 – C$230.27 |
| 60 trading days | C$210.89 | C$171.19 – C$259.79 |
| 90 trading days | C$223.82 | C$173.37 – C$288.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should monitor the implications of this study on Guardant Health's market position and financial performance.
Guardant Health's stock rose 5.30% following the study announcement.
With a last close of US$171.59, the stock has increased by 15.99% over the past month.
Bull case
The COSMOS study's validation may boost the credibility and adoption of Guardant's liquid biopsy test. This could lead to increased revenue as more healthcare professionals recognize its value in predicting melanoma recurrence.
Bear case
Despite the positive results from the study, Guardant Health faces ongoing financial losses and a high negative return on equity, which may raise concerns for investors.
COSMOS Study Published in Cancer Research Communications
Advertisement
Guardant Health's COSMOS study has been published in Cancer Research Communications, showcasing the effectiveness of its Guardant Reveal™ liquid biopsy test in predicting recurrence in melanoma patients. This publication is expected to enhance the test's credibility among healthcare professionals, potentially leading to greater adoption in clinical settings. The study's findings could significantly impact treatment protocols, especially as healthcare increasingly shifts towards personalized medicine.
Stock Performance Following the Announcement
Following the publication of the study, Guardant Health's stock price rose by 5.30%, closing at US$171.59. The trading volume was 2,410,513 shares, slightly below the 20-day average volume of 1,835,345 shares, indicating healthy trading activity despite the lower volume relative to the average. Over the past month, the stock has appreciated by 15.99%, reflecting positive investor sentiment regarding the study's implications. The stock is currently trading 3.8% above its 50-day moving average of US$165.33 and 38.5% above its 200-day moving average of US$123.93.
Future Implications to Watch
Investors should keep an eye on how the publication of the COSMOS study influences Guardant Health's market share and revenue generation in the oncology sector. The company has a market capitalization of approximately $25.12 billion, and analyst targets suggest an average price target of US$199.04, indicating an implied upside of 16.0%. Additionally, the stock is currently trading within 87% of its 52-week range of US$61.00 to US$187.69, which may offer insights into its valuation and future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
